FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mary Ann Mascelli

Research Profile

Chemicals & Drugs

Physiology

Platelet Aggregation

Anatomy

Blood Platelets

Procedures

Concepts & Ideas

Disorders

Co-author Network

Publications

TOP 3
Newman Yeilding; Honghui Zhou; Jacqueline Benson; Carrie Brodmerkel; Jill Giles-Komar; Kavitha Goyal; Mary Ann Mascelli; Michael Plotnick; Brad Schenkel; Philippe Szapary; Cynthia Guzzo
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Jacqueline M Benson; Jill M Giles-Komar; George A Heavner; David Peritt; Bernard J Scallon; David Shealy; Mary Ann Mascelli
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Jacqueline M Benson; Carrie M Brodmerkel; Charles Pendley; Clifford W Sachs; Gopi Shankar; George Treacy; Honghui Zhou; Mary Ann Mascelli
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mary Ann Mascelli (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Newman Yeilding; Honghui Zhou; Jacqueline Benson; Carrie Brodmerkel; Jill Giles-Komar; Kavitha Goyal; Mary Ann Mascelli; Michael Plotnick; Brad Schenkel; Philippe Szapary; Cynthia Guzzo
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Annals of the New York Academy of Sciences 2012;1263():1-12.
2011: Jacqueline M Benson; Jill M Giles-Komar; George A Heavner; David Peritt; Bernard J Scallon; David Shealy; Mary Ann Mascelli
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
mAbs 2011;3(6):535-45.
2011: Jacqueline M Benson; Carrie M Brodmerkel; Charles Pendley; Clifford W Sachs; Gopi Shankar; George Treacy; Honghui Zhou; Mary Ann Mascelli
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
Nature biotechnology 2011;29(7):615-24.
2011: Newman Yeilding; Philippe Szapary; Carrie Brodmerkel; Jacqueline Benson; Michael Plotnick; Honghui Zhou; Kavitha Goyal; Brad Schenkel; Jill Giles-Komar; Mary Ann Mascelli; Cynthia Guzzo
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Annals of the New York Academy of Sciences 2011;1222():30-9.
2011: Honghui Zhou; Mary Ann Mascelli
Mechanisms of monoclonal antibody-drug interactions.
Annual review of pharmacology and toxicology 2011;51():359-72.
2010: Carrie Brodmerkel; Yaowei Zhu; Qun Jiao; Joel Cornacoff; George Treacy; Mary Ann Mascelli; Alice B Gottlieb
Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions.
Journal of drugs in dermatology : JDD 2010;9(6):677-83.
2007: Alice B Gottlieb; Kevin D Cooper; Thomas S McCormick; Eiko Toichi; Daniel E Everitt; Bart Frederick; Yaowei Zhu; Charles Pendley; Martin A Graham; Mary Ann Mascelli
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
Current medical research and opinion 2007;23(5):1081-92.
2007: Mary Ann Mascelli; Honghui Zhou; Raymond Sweet; Jay Getsy; Hugh M Davis; Martin Graham; Darrell R. Abernethy
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
Journal of clinical pharmacology 2007;47(5):553-65.
2007: Honghui Zhou; Haishan Jang; Roy M Fleischmann; Esther Bouman-Thio; Zhenhua Xu; Joseph C Marini; Charles Pendley; Qun Jiao; Gopi Shankar; Stanley J Marciniak; Stanley B Cohen; Mahboob U Rahman; Daniel Baker; Mary Ann Mascelli; Hugh M Davis; Daniel E Everitt
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Journal of clinical pharmacology 2007;47(3):383-96.
2006: Eiko Toichi; Gisela Torres; Thomas S McCormick; Timothy Chang; Mary Ann Mascelli; Catharine Lisa Kauffman; Nancy Aria; Alice B Gottlieb; Daniel E Everitt; Bart Frederick; Charles Pendley; Kevin D Cooper
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(7):4917-26.
2006: Lloyd H Kasper; Daniel E Everitt; Thomas P Leist; Kathleen A Ryan; Mary Ann Mascelli; Kenneth P Johnson; Aparna Raychaudhuri; Tim Vollmer
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
Current medical research and opinion 2006;22(9):1671-8.
2006: René Westhovens; Frédéric A Houssiau; Johan Joly; Daniel E Everitt; Yaowei Zhu; Deborah Sisco; Bart Van Hartingsveldt; Mary Ann Mascelli; Martin A Graham; Patrick Durez; Esther Bouman-Thio
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
The Journal of rheumatology 2006;33(5):847-53.
2004: Mary Ann Mascelli; Efthymios Deliargyris; Lakshmi V Damaraju; Elliot S Barnathan; Robert M Califf; Maarten L Simoons; David C Sane
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes.
Journal of thrombosis and thrombolysis 2004;18(3):171-5.
2004: Catharine Lisa Kauffman; Nancy Aria; Eiko Toichi; Thomas S McCormick; Kevin D Cooper; Alice B Gottlieb; Daniel E Everitt; Bart Frederick; Yaowei Zhu; Martin A Graham; Charles Pendley; Mary Ann Mascelli
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
The Journal of investigative dermatology 2004;123(6):1037-44.
2004: Mary Ann Mascelli; Efthymios Deliargyris; Lakshmi V Damaraju; Elliot S Barnathan; David C Sane
Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes.
Seminars in thrombosis and hemostasis 2004;30(3):347-50.
2004: Jean-Pierre Dery; Gregory A Braden; A Michael Lincoff; Dean J Kereiakes; Kevin Browne; Thomas Little; Barry S George; David C Sane; Douglas B Cines; Mark B Effron; Mary Ann Mascelli; Mary Ann Langrall; Lakshmi V Damaraju; Elliot S Barnathan; James E Tcheng
Final results of the ReoPro readministration registry.
The American journal of cardiology 2004;93(8):979-84.
2004: Subrata Chakrabarti; Patricia Clutton; Sonia Varghese; Dermot Cox; Mary Ann Mascelli; Jane E Freedman
Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Thrombosis research 2004;113(3-4):225-33.
2004: Mirna Urquidi-Macdonald; Donald E Mager; Mary Ann Mascelli; Bart Frederick; Jane Freedman; Desmond J Fitzgerald; Neal S Kleiman; Darrell R. Abernethy
Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability.
Clinical pharmacology and therapeutics 2004;75(1):60-9.
2003: Donald E Mager; Mary Ann Mascelli; Neal S Kleiman; Desmond J Fitzgerald; Darrell R. Abernethy
Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
The Journal of pharmacology and experimental therapeutics 2003;307(3):969-76.
2003: R Taylor Williams; Lakshmi V Damaraju; Mary Ann Mascelli; Elliot S Barnathan; Robert M Califf; Maarten L Simoons; Efthymios Deliargyris; David C Sane
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes.
Circulation 2003;107(18):2307-12.
2003: C L Wagner; A Schantz; Elliot S Barnathan; A Olson; Mary Ann Mascelli; J Ford; Lakshmi V Damaraju; Thomas Schaible; R N Maini; J E Tcheng
Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.
Developments in biologicals 2003;112():37-53.
2002: Stanley J Marciniak; Mary Ann Mascelli; Mark I Furman; Alan D Michelson; Joseph A Jakubowski; Robert E Jordan; Peter J Marchese; Andrew L Frelinger
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Thrombosis and haemostasis 2002;87(6):1020-5.
2002: Darrell R. Abernethy; John Pezzullo; Mary Ann Mascelli; Bart Frederick; Neal S Kleiman; Jane Freedman
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
Clinical pharmacology and therapeutics 2002;71(3):186-95.
2002: Jane Freedman; Mary Ann Mascelli; John C Pezzullo; Elliot S Barnathan; Bart Frederick; Robert E Jordan; Darrell R. Abernethy
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
American heart journal 2002;143(1):87-94.
2002: Guy L Wheeler; Gregory A Braden; Paul F Bray; Stanley J Marciniak; Mary Ann Mascelli; David C Sane
Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.
American heart journal 2002;143(1):76-82.
2001: James E Tcheng; Dean J Kereiakes; A Michael Lincoff; Barry S George; Neal S Kleiman; David C Sane; Douglas B Cines; Robert E Jordan; Mary Ann Mascelli; Mary Ann Langrall; Lakshmi V Damaraju; A Schantz; Mark B Effron; Gregory A Braden
Abciximab readministration: results of the ReoPro Readministration Registry.
Circulation 2001;104(8):870-5.
2001: A Michael Lincoff; Dean J Kereiakes; Mary Ann Mascelli; L I Deckelbaum; Elliot S Barnathan; K K Patel; Bart Frederick; Marian T Nakada; Eric J Topol
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
Circulation 2001;104(2):163-7.
2001: Sebastian Harder; Ute Klinkhardt; Jochen Graff; Dagmar Westrup; Carl M Kirchmaier; E Glusa; Mary Ann Mascelli; Stanley J Marciniak; A Just; W Lösche; Hans Klaus Breddin
In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
Thrombosis research 2001;102(1):39-48.
2001: Stanley J Marciniak; Robert E Jordan; Mary Ann Mascelli
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Thrombosis and haemostasis 2001;85(3):539-43.
2000: Mark I Furman; Lori A Krueger; Andrew L Frelinger; Marc R Barnard; Mary Ann Mascelli; Marian T Nakada; Alan D Michelson
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Thrombosis and haemostasis 2000;84(3):492-8.
2000: Neal S Kleiman; N Grazeiadei; Kelly Maresh; R J Taylor; Bart Frederick; ET Lance; Mark B Effron; Robert E Jordan; Mary Ann Mascelli
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
American heart journal 2000;140(3):492-501.
2000: David C Sane; Lakshmi V Damaraju; Eric J Topol; C F Cabot; Mary Ann Mascelli; Robert A Harrington; Maarten L Simoons; Robert M Califf
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
Journal of the American College of Cardiology 2000;36(1):75-83.
2000: SA Coulter; Christopher P Cannon; K A Ault; Elliott M Antman; Frans Van de Werf; A A Jennifer Adgey; C Michael Gibson; Robert P Giugliano; Mary Ann Mascelli; J Scherer; Elliot S Barnathan; Eugene Braunwald; N S Kleiman
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
Circulation 2000;101(23):2690-5.
2000: Mary Ann Mascelli; Neal S Kleiman; Stanley J Marciniak; Lakshmi V Damaraju; HF Weisman; Robert E Jordan
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
American heart journal 2000;139(4):696-703.
2000: BJ Fredrickson; Nancy A Turner; Neal S Kleiman; N Graziadei; Kelly Maresh; Mary Ann Mascelli; Mark B Effron; Larry V McIntire
Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty.
Circulation 2000;101(10):1122-9.
2000: Alan D Michelson; M I Furman; Pascal J Goldschmidt-Clermont; Mary Ann Mascelli; Craig W Hendrix; L Coleman; J Hamlington; M R Barnard; Thomas S Kickler; D J Christie; S Kundu; Paul F Bray
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Circulation 2000;101(9):1013-8.
2000: Neal S Kleiman; N Graziadei; Robert E Jordan; ET Lance; A Fischer; Kelly Maresh; A Edwards; Mary Ann Mascelli
Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro.
Journal of thrombosis and thrombolysis 2000;9(1):29-36.
1999: J R Leclerc; Mary Ann Mascelli; HF Weisman
Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease.
Coronary artery disease 1999;10(8):575-9.
1999: James E Tcheng; Dean J Kereiakes; Gregory A Braden; Robert E Jordan; Mary Ann Mascelli; Mary Ann Langrall; Mark B Effron
Readministration of abciximab: interim report of the ReoPro readministration registry.
American heart journal 1999;138(1 Pt 2):S33-8.
1998: Mary Ann Mascelli; ET Lance; Lakshmi V Damaraju; C L Wagner; HF Weisman; Robert E Jordan
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
Circulation 1998;97(17):1680-8.
1997: Mary Ann Mascelli; S Worley; N J Veriabo; ET Lance; S Mack; Thomas Schaible; HF Weisman; Robert E Jordan
Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Circulation 1997;96(11):3860-6.
1996: C L Wagner; Mary Ann Mascelli; D S Neblock; HF Weisman; Barry S Coller; Robert E Jordan
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
Blood 1996;88(3):907-14.
1993: W C Bogard; S A Siegel; A O Leone; E Damiano; D J Shealy; T M Ely; B Frederick; Mary Ann Mascelli; R C Siegel; B Machielse
Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(10):4438-49.
1993: Mary Ann Mascelli; B Frederick; T Ely; D S Neblock; D J Shealy; Koon Pak; P E Daddona
Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.
Infection and immunity 1993;61(5):1756-63.
1992: D S Neblock; C H Chang; Mary Ann Mascelli; M Fleek; L Stumpo; M M Cullen; P E Daddona
Conjugation and evaluation of 7E3 x P4B6, a chemically cross-linked bispecific F(ab')2 antibody which inhibits platelet aggregation and localizes tissue plasminogen activator to the platelet surface.
Bioconjugate chemistry 1992;3(2):126-31.